Revenue and Profitability - The company's revenue for Q1 2022 was RMB 629,519,132.31, representing a decrease of 61.02% compared to the same period last year[5] - The net loss attributable to shareholders was RMB -396,395,486.59, a decline of 205.06% year-over-year[5] - The basic and diluted earnings per share were both -0.44 yuan, reflecting a decline of 202.33% year-over-year[5] - The net profit attributable to shareholders of the parent company for Q1 2022 was -396,395,486.59 CNY, compared to 377,321,280.11 CNY in Q1 2021, indicating a significant decline[19] - The total comprehensive income for Q1 2022 was -471,770,135.33 CNY, compared to 379,422,645.53 CNY in Q1 2021, reflecting a substantial decrease[19] Cash Flow - The net cash flow from operating activities was RMB 570,432,127.10, an increase of 42.75% compared to the previous year[5] - Cash flow from operating activities in Q1 2022 was 1,544,045,956.19 CNY, slightly down from 1,572,798,247.65 CNY in Q1 2021[20] - The net cash flow from operating activities for Q1 2022 was 570,432,127.10 CNY, compared to 399,613,641.51 CNY in Q1 2021, showing an improvement[20] - The net cash flow from investing activities for Q1 2022 was -175,320,677.30 CNY, compared to -489,544,165.73 CNY in Q1 2021, indicating reduced cash outflow[20] - The net cash flow from financing activities for Q1 2022 was 357,189,314.87 CNY, compared to -18,839,104.49 CNY in Q1 2021, showing a positive shift[20] - The cash and cash equivalents at the end of Q1 2022 amounted to 4,258,353,489.75 CNY, up from 3,282,286,048.21 CNY at the end of Q1 2021[21] - The company received 380,000,000.00 CNY from investments in Q1 2022, marking a significant inflow compared to the previous year[20] Research and Development - Research and development expenses totaled RMB 510,912,040.65, accounting for 81.16% of revenue, which is an increase of 53.26 percentage points year-over-year[6] - R&D expenses increased to ¥510,912,040.65 in Q1 2022, compared to ¥450,649,443.76 in Q1 2021, reflecting a growth of 13%[18] Assets and Liabilities - The total assets at the end of the reporting period were RMB 10,953,222,268.79, a slight decrease of 0.74% from the end of the previous year[6] - Total assets as of Q1 2022 were ¥10,953,222,268.79, slightly down from ¥11,034,911,100.95 at the end of the previous period[17] - Total liabilities amounted to ¥2,651,629,271.81 in Q1 2022, compared to ¥2,718,536,814.27 in the previous period[16] - The company reported a decrease in total equity to ¥8,301,592,996.98 from ¥8,316,374,286.68[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,735, with HKSCC NOMINEES LIMITED holding 24.08% of shares[10] Other Income - The company reported non-operating income of RMB 33,187,838.62, primarily from non-current asset disposal gains and government subsidies[7] - The company reported a decrease in other comprehensive income, with a net amount of -50,581,534.74 CNY for Q1 2022, compared to 2,101,658.95 CNY in Q1 2021[19] Inventory and Receivables - Accounts receivable decreased to ¥352,440,767.40 from ¥1,293,122,136.21, indicating a significant reduction of 73%[15] - Inventory increased to ¥509,224,927.05 from ¥484,601,367.48, showing a growth of 5%[15]
君实生物(01877) - 2022 Q1 - 季度财报